What can HIV vaccine trials teach us about future HIV vaccine dissemination?
What can HIV vaccine trials teach us about future HIV vaccine dissemination?
复制标题
关于未来艾滋病毒疫苗的传播，艾滋病毒疫苗试验可以告诉我们什么？
DOI：
10.1016/j.vaccine.2008.03.004
复制
发表时间：
2008
期刊：
影响因子：
5.5
通讯作者：
Roberts,Kathleen
中科院分区：
文献类型：
--
作者：
Newman,PeterA;Duan,Naihua;Kakinami,Lisa;Roberts,Kathleen
本研究探讨了HIV疫苗试验参与的障碍和动机的共性和差异以及未来美国食品和药物管理局（FDA）批准的HIV疫苗的可接受性，以确定临床试验对未来HIV疫苗传播的影响。在洛杉矶进行了15个焦点小组，157名主要是少数民族和低收入参与者，采用基于场地的抽样方法招募。采用叙事主题分析法对数据进行分析。参与HIV疫苗试验意愿（WTP）和未来HIV疫苗可接受性的共同障碍和动机（例如，对疫苗引起的感染、假阳性、副作用、疗效、不信任和耻辱的担忧）表明，临床试验为开发和评估基于经验的干预措施提供了重要机会，以支持未来的艾滋病毒疫苗传播。艾滋病毒疫苗可接受性的具体障碍（例如，对保护期限、跨分支保护、费用和获取的关切）也表明，需要进行专门侧重于未来传播的形成性研究。保护的动机，共同的WTP和可接受性，强调需要提供和评估预防咨询和教育的临床试验，这可能会形成证据知情的预防干预措施的基础上推出的配合传播部分功效的艾滋病毒疫苗。
This investigation explored commonalities and differences in barriers and motivators to HIV vaccine trial participation and acceptability of future United States Food and Drug Administration (FDA)-approved HIV vaccines in order to identify implications of clinical trials for future HIV vaccine dissemination. Fifteen focus groups were conducted with 157 predominately ethnic minority and low income participants recruited using venue-based sampling in Los Angeles. Data were analyzed using narrative thematic analysis. Barriers and motivators in common across willingness to participate (WTP) in HIV vaccine trials and future HIV vaccine acceptability (e.g., concerns about vaccine-induced infection, false-positives, side effects, efficacy, mistrust and stigma) suggest clinical trials present significant opportunities to develop and evaluate empirically based interventions to support future HIV vaccine dissemination. Barriers specific to HIV vaccine acceptability (e.g., concerns about duration of protection, cross-clade protection, cost and access) also indicate the need for formative research focused specifically on future dissemination. Protection motivation, common to WTP and acceptability, highlights the need to provide and evaluate prevention counseling and education in clinical trials, which may form the basis of evidence-informed preventive interventions to be launched in tandem with dissemination of partial efficacy HIV vaccines.